A new era in the diagnosis and treatment of atypical haemolytic uraemic syndrome

Netherlands Journal of Medicine

Volumn 70, Issue 3, 2012, Pages 121-129

  Westra, D ^a   Wetzels, J F M ^a   Volokhina, E B ^a   van den Heuvel, L P ^a   van de Kar, N C A J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Atypical haemolytic uraemic syndrome; Complement system; Eculizumab; Kidney transplantation; Plasma therapy

Indexed keywords

COMPLEMENT; ECULIZUMAB;

COMPLEMENT SYSTEM; DIARRHEA; DRUG APPROVAL; DRUG BINDING; DRUG COST; DRUG TOLERABILITY; HEMOLYTIC UREMIC SYNDROME; HUMAN; HYPERTENSION; KIDNEY TRANSPLANTATION; LOSS OF FUNCTION MUTATION; PATHOGENESIS; PATIENT CARE; PENETRANCE; PERSONALIZED MEDICINE; PLASMAPHERESIS; REVIEW; SINGLE DRUG DOSE; UPPER RESPIRATORY TRACT INFECTION;

ANTIBODIES, MONOCLONAL, HUMANIZED; COMPLEMENT INACTIVATING AGENTS; COMPLEMENT SYSTEM PROTEINS; HEMOLYTIC-UREMIC SYNDROME; HUMANS; MUTATION; PROGNOSIS; TREATMENT OUTCOME;

EID: 84860141031     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Besbas N, Karpman D, Landau D, et al. A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. Kidney Int. 2006;70(3):423-31.
2. Keir L, Coward RJ. Advances in our understanding of the pathogenesis of glomerular thrombotic microangiopathy. Pediatr Nephrol. 2011;26(4):523-33.
3. Noris M, Remuzzi G. Hemolytic uremic syndrome. J Am Soc Nephrol. 2005;16(4):1035-50.
4. Garg AX, Suri RS, Barrowman N, et al. The long-term renal prognosis of diarrhea associated hemolytic uremic syndrome: A systematic review, meta-analysis and meta-regression of 3476 children from 49 studies. J Am Soc Nephrol. 2003;14:299a-a.
5. Frank C, Werber D, Cramer JP, et al. Epidemic profle of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany. N Engl J Med. 2011;365(19):1771-80.
6. Kemper MJ. Outbreak of hemolytic uremic syndrome caused by E. coli O104:H4 in Germany: a pediatric perspective. Pediatr Nephrol. 2012;27(2):161-4.
7. Kavanagh D, Goodship TH, Richards A. Atypical haemolytic uraemic syndrome. Br Med Bull. 2006;77-78:5-22.
8. Jokiranta TS, Zipfel PF, Fremeaux-Bacchi V, Taylor CM, Goodship TJ, Noris M. Where next with atypical hemolytic uremic syndrome? Mol Immunol. 2007;44(16):3889-900.
9. Tsai HM, Chandler WL, Sarode R, et al. Von Willebrand factor and von Willebrand factor-cleaving metalloprotease activity in Escherichia coli O157: H7-associated hemolytic uremic syndrome. Pediatr Res. 2001;49(5):653-9.
10. Mannucci PM, Franchini M. Advantages and limits of ADAMTS13 testing in the prognostic assessment of thrombotic thrombocytopenic purpura. Presse Med. 2012.
11. Cameron JS, Vick R. Letter: Plasma-C3 in haemolytic-uraemic syndrome and thrombotic thrombocytopenic purpura. Lancet. 1973;2(7835):975.
12. Monnens L, Molenaar J, Lambert PH, Proesmans W, van Munster P. The complement system in hemolytic-uremic syndrome in childhood. Clin Nephrol. 1980;13(4):168-71.
13. Walport MJ. Complement. First of two parts. N Engl J Med. 2001;344(14):1058-66.
14. Walport MJ. Complement. Second of two parts. N Engl J Med. 2001;344(15):1140-4.
15. Warwicker P, Goodship THJ, Donne RL, et al. Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int. 1998;53(4):836-44.
16. Noris M, Brioschi S, Caprioli J, et al. Familial haemolytic uraemic syndrome and an MCP mutation. Lancet. 2003;362(9395):1542-7.
17. Fremeaux-Bacchi V, Dragon-Durey MA, Blouin J, et al. Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome. J Med Genet. 2004;41(6):e84.
18. Caprioli J, Noris M, Brioschi S, et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood. 2006;108(4):1267-79.
19. Westra D, Volokhina E, van der Heijden E, et al. Genetic disorders in complement (regulating) genes in patients with atypical haemolytic uraemic syndrome (aHUS). Nephrol Dial Transplant. 2010;25(7):2195-202.
20. Delvaeye M, Noris M, De Vriese A, et al. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med. 2009;361(4):345-57.
21. De Goicoechea JE, Harris CL, Esparza-Gordillo J, et al. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci U S A. 2007;104(1):240-5.
22. Fremeaux-Bacchi V, Miller EC, Liszewski MK, et al. Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood. 2008;112(13):4948-52.
23. Esparza-Gordillo J, Goicoechea de Jorge E, Buil A, et al. Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32. Hum Mol Genet. 2005;14(5):703-12.
24. Jozsi M, Licht C, Strobel S, et al. Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood. 2008;111(3):1512-4.
25. Jozsi M, Strobel S, Dahse HM, et al. Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome. Blood. 2007;110(5):1516-8.
26. Ariceta G, Besbas N, Johnson S, et al. Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatr Nephrol. 2009;24(4):687-96.
27. Taylor CM, Machin S, Wigmore SJ, Goodship TH. Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom. Br J Haematol. 2010;148(1):37-47.
28. Saunders RE, Goodship TH, Zipfel PF, Perkins SJ. An interactive web database of factor H-associated hemolytic uremic syndrome mutations: insights into the structural consequences of disease-associated mutations. Hum Mutat. 2006;27(1):21-30.
29. Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet. 2005;365(9464):1073-86.
30. Noris M, Remuzzi G. Atypical hemolyticuremic syndrome. N Engl J Med. 2009;361(17):1676-87.
31. Caprioli J, Castelletti F, Bucchioni S, et al. Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. Hum Mol Genet. 2003;12(24):3385-95.
32. Geerdink LM, Westra D, van Wijk JAE, et al. Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristics. Pediatr Nephrol. 2012 Mar 13.
33. Olie KH, Goodship THJ, Verlaak R, et al. Posttransplantation cytomegalovirus-induced recurrence of atypical hemolytic uremic syndrome associated with a factor H mutation: Successful treatment with intensive plasma exchanges and ganciclovir. Am J Kidney Dis. 2005;45(1):E12-E5.
34. Artz MA, Steenbergen EJ, Hoitsma AJ, Monnens LAH, Wetzels JFM. Renal transplantation in patients with hemolytic uremic syndrome: High rate of recurrence increased incidence of acute rejections. Transplantation. 2003;76(5):821-6.
35. Loirat C, Fremeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis. 2011;6(1):60.
36. Davin JC, Strain L, Goodship THJ. Plasma therapy in atypical haemolytic uremic syndrome: lessons from a family with a factor H mutation. Pediatr Nephrol. 2008;23(9):1517-21.
37. Donne RL, Abbs I, Barany P, et al. Recurrence of hemolytic uremic syndrome after live related renal transplantation associated with subsequent de novo disease in the donor. Am J Kidney Dis. 2002;40(6):E22.
38. Zuber J, Le Quintrec M, Sberro-Soussan R, Loirat C, Fremeaux-Bacchi V, Legendre C. New insights into postrenal transplant hemolytic uremic syndrome. Nature Rev Nephrol. 2011;7(1):23-35.
39. Hillmen P, Hall C, Marsh JC, et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2004;350(6):552-9.
40. Kose O, Zimmerhackl LB, Jungraithmayr T, Mache C, Nurnberger J. New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab. Semin Thromb Hemost. 2010;36(6):669-72.
41. Legendre CM, Babu S, Furman RR, et al. Safety and efficacy of eculizumab in aHUS patients resistant to plasma therapy: interim analysis from a phase II trial (SA-FC406) [abstract]. J Am Soc Nephrol. 2010;21:93A.
42. Muus P, Legendre C, Douglas K, et al. Safety and efficacy of eculizumab in aHUS patients on chronic plasma therapy: interim analysis of a phase II trial (F-PO1274) [abstract]. J Am Soc Nephrol. 2010;21:402A.
43. Bouts A, Monnens L, Davin JC, Struijk G, Spanjaard L. Insufficient protection by Neisseria meningitidis vaccination alone during eculizumab therapy. Pediatr Nephrol. 2011;26(10):1919-20.